Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose vs Standard Dose PTCy in Alternative Donor Allo-HSCT
NCT06705062Phase 3Recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Jan 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cyclophosphamide in graft-versus-host disease (GVHD), sponsored by Shanghai Jiao Tong University School of Medicine. Started Jan 2025; status: recruiting.
02
Drugs
cyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06705062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06705062.